Can selective serotonin reuptake inhibitors (SSRIs) cause Stevens‑Johnson syndrome, and how should it be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Stevens-Johnson Syndrome from SSRIs

Yes, SSRIs can cause Stevens-Johnson syndrome (SJS), though it is rare, and immediate discontinuation of the suspected SSRI is the most critical intervention to prevent progression to life-threatening toxic epidermal necrolysis (TEN).

Can SSRIs Cause SJS?

SSRIs are documented causes of SJS/TEN, though the association is uncommon. Multiple SSRIs have been implicated:

  • Fluoxetine has been specifically associated with potential SJS risk 1, 2
  • Fluvoxamine has documented cases of SJS/TEN 2
  • Paroxetine has been reported to cause severe cutaneous reactions 2
  • Citalopram has been linked to keratinocyte necrosis and dermal leukocytoclastic vasculitis 2
  • Sertraline showed increased psychiatric symptom reporting but dermatological reactions were documented 3

The evidence suggests cross-reactivity between different SSRIs despite their different chemical structures 1, 2. This means if one SSRI causes SJS, switching to another SSRI is contraindicated—you must use a different class of antidepressant entirely 1, 2.

Recognition and Diagnosis

Timeline and Presentation

The latent period between drug initiation and SJS/TEN onset is typically 5-28 days after starting the medication 4. Look for:

  • Prodromal symptoms: fever, malaise, upper respiratory symptoms 4
  • Painful rash initially on face and chest 4
  • Mucosal involvement: eyes, mouth, nose, genitalia 4
  • Target lesions (particularly atypical targets), purpuric macules, blisters, and epidermal detachment 4

Diagnostic Workup

When SJS is suspected 4:

  1. Skin biopsy from lesional skin adjacent to blister for histopathology
  2. Second biopsy from periblister lesional skin (unfixed) for direct immunofluorescence to exclude immunobullous disorders
  3. Full blood count, liver/kidney function, coagulation studies, mycoplasma serology
  4. Chest X-ray
  5. Document extent of erythema and epidermal detachment separately on body map using Lund and Browder chart
  6. Photograph skin lesions

Histopathology shows: multiple apoptotic keratinocytes throughout full-thickness epidermis, subepidermal split forming bulla, perivascular lymphocytic infiltrate 4

Immediate Management

Critical First Steps 4

Discontinue the suspected SSRI immediately—this is the single most important intervention. Do not wait for confirmatory testing.

  1. Stop all potential culprit drugs immediately
  2. Establish IV access through non-lesional skin if possible
  3. Begin fluid resuscitation if clinically indicated with strict fluid charting
  4. Insert nasogastric tube if patient cannot maintain oral hydration/nutrition
  5. Insert urinary catheter if urogenital involvement causes dysuria/retention (also permits accurate output monitoring)

Prognostic Assessment

Use SCORTEN to predict mortality risk 4. One point for each parameter:

  • Age >40 years
  • Malignancy
  • Heart rate >120 bpm
  • Initial BSA detachment >10%
  • Serum urea >10 mmol/L
  • Serum glucose >14 mmol/L
  • Serum bicarbonate <20 mmol/L

Higher scores predict higher mortality—this guides intensity of care and need for ICU/burn unit transfer.

Specialized Care

Transfer to intensive care unit or burn center for severe cases 4. Early transfer to specialist units improves outcomes; delayed transfer is associated with increased mortality 4.

Critical Pitfalls

  1. Do NOT rechallenge with any SSRI if SJS occurred—cross-reactivity means all SSRIs are contraindicated 1, 2
  2. Do NOT delay drug discontinuation waiting for biopsy results—clinical suspicion is sufficient 4
  3. Do NOT underestimate mucosal involvement—examine all mucosal sites systematically 4
  4. Do NOT confuse with erythema multiforme major—SJS has more extensive mucosal involvement and different distribution 4

Long-term Considerations

After recovery, the patient must:

  • Avoid the culprit SSRI permanently and all drugs in the same class 4
  • Carry documentation of the drug allergy
  • Be monitored for chronic sequelae including ocular complications (most common), which benefit from early ophthalmology referral 4

If antidepressant therapy remains necessary, switch to a different class entirely (e.g., tricyclics, bupropion, mirtazapine if not previously implicated) 1, 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.